BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 526939)

  • 1. Phase II evaluation of maytansine in patients with advanced head and neck cancer.
    Creagan ET; Fleming TR; Edmonson JH; Ingle JN
    Cancer Treat Rep; 1979; 63(11-12):2061-2. PubMed ID: 526939
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I study of weekly maytansine given by iv bolus or 24-hour infusion.
    Chahinian AP; Nogeire C; Ohnuma T; Greenberg ML; Sivak M; Jaffrey IS; Holland JF
    Cancer Treat Rep; 1979; 63(11-12):1953-60. PubMed ID: 526928
    [No Abstract]   [Full Text] [Related]  

  • 3. A therapeutic trial of maytansine.
    Blum RH; Wittenberg BK; Canellos GP; Mayer RJ; Skarin AT; Henderson IC; Parker LM; Frei E
    Cancer Clin Trials; 1978; 1(2):113-7. PubMed ID: 757139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of maytansine in patients with metastatic lung cancer.
    Eagan RT; Creagan ET; Ingle JN; Frytak S; Rubin J
    Cancer Treat Rep; 1978 Oct; 62(10):1577-9. PubMed ID: 709559
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of maytansine in advanced breast cancer.
    Edmonson JH; Rubin J; Kvols LK; O'Connell MJ; Frytak S; Green SJ
    Cancer Treat Rep; 1981; 65(5-6):536-7. PubMed ID: 7237478
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II trial of maytansine in patients with advanced colorectal carcinoma.
    O'Connell MJ; Shani A; Rubin J; Moertel CG
    Cancer Treat Rep; 1978 Aug; 62(8):1237-8. PubMed ID: 356981
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II study of maytansine in advanced sarcomas.
    Edmonson JH; Hahn RG; Creagan ET; O'Connell MJ
    Cancer Treat Rep; 1983 Apr; 67(4):401-2. PubMed ID: 6850657
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I study of maytansine using a 3-day schedule.
    Cabanillas F; Rodriguez V; Hall SW; Burgess MA; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1978 Mar; 62(3):425-8. PubMed ID: 348310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.
    Rosenthal S; Harris DT; Horton J; Glick JH
    Cancer Treat Rep; 1980; 64(10-11):1115-7. PubMed ID: 7459897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of vindesine in advanced squamous cell cancer of the head and neck.
    Vogl SE; Camacho FJ; Kaplan BH; O'Donnell MR
    Cancer Treat Rep; 1984 Mar; 68(3):559-60. PubMed ID: 6704987
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II trial of pyrazofurin in advanced head and neck cancer.
    Cheng E; Currie V; Wittes RE
    Cancer Treat Rep; 1979; 63(11-12):2047-8. PubMed ID: 526937
    [No Abstract]   [Full Text] [Related]  

  • 12. Maytansine: a phase I study of an ansa macrolide with antitumor activity.
    Blum RH; Kahlert T
    Cancer Treat Rep; 1978 Mar; 62(3):435-8. PubMed ID: 348312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a phase II study of maytansine in patients with breast carcinoma and melanoma.
    Cabanillas F; Bodey GP; Burgess MA; Freireich EJ
    Cancer Treat Rep; 1979 Mar; 63(3):507-9. PubMed ID: 371803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m--anisidine (AMSA) in patients with advanced head and neck cancers.
    Ratanatharathorn V; Drelichman A; Sexon-Porte M; Al-Sarraf M
    Am J Clin Oncol; 1982 Feb; 5(1):29-32. PubMed ID: 6896258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aclacinomycin. Phase II evaluation in advanced squamous carcinoma of the head and neck.
    Kish JA; Al-Sarraf M
    Am J Clin Oncol; 1984 Oct; 7(5):535-7. PubMed ID: 6507374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoguazone in advanced squamous cell carcinoma of head and neck origin: a phase II trial of the Southeastern Cancer Study Group.
    Luedke DW; Maddox W; Birch R; Velez-Garcia E; Schleuter J
    Cancer Treat Rep; 1986 Apr; 70(4):529-30. PubMed ID: 3698048
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma.
    Ahmann DL; Frytak S; Kvols LK; Hahn RG; Edmonson JH; Bisel HF; Creagan ET
    Cancer Treat Rep; 1980; 64(4-5):721-3. PubMed ID: 6448689
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.
    Edmonson JH; Frytak S; Letendre L; Kvols LK; Eagan RT
    Cancer Treat Rep; 1979; 63(11-12):2081-3. PubMed ID: 526941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial clinical trials of maytansine, an antitumor plant alkaloid.
    Chabner BA; Levine AS; Johnson BL; Young RC
    Cancer Treat Rep; 1978 Mar; 62(3):429-33. PubMed ID: 348311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.